Medical device company Medovate is partnering with the New York School of Regional Anesthesia (NYSORA) to support the launch of SAFIRA in the US.
SAFIRA (SAFer Injection for Regional Anesthesia) is an approved new technology that transforms regional anaesthesia into a one person procedure, putting control in the hands of the anesthesiologist.
A unique safety solution monitors and limits injection pressure. This helps to improve patient safety by reducing the risk of patient nerve damage resulting from accidental intraneural injection.
Developed in collaboration with anaesthesiologists in the UK National Health Service (NHS), Medovate is launching technology initially in the US. Three US-based companies have already signed agreements to act as exclusive distributors.
Chris Rogers, sales and marketing director at Medovate, commented: “Medovate are delighted to be working with NYSORA. We believe they are a great fit for us to help position the unique benefits in patient safety and cost optimisation that SAFIRA will provide to anaesthesiologists across the United States. We are looking forward to building a close relationship as SAFIRA is launched in the coming weeks.”
Professor Dr Admir Hadžić, president, NYSORA, commented: “Being at the forefront of the developments in regional anaesthesia for nearly three decades, NYSORA has always supported improvements in technology and safety in regional anaesthesia.”
“With the Covid-19 pandemic, nerve blocks have emerged as the anaesthesia of choice for emergency extremity surgery and a modality that can help re-establish elective orthopedic outpatient surgery programmes. We are delighted to partner with Medovate and their milestone development in remote-controlled local anesthetic administration and injection pressure monitoring systems for more efficient and safer practice of nerve blocks.”
